by kshughes | Mar 3, 2016 | Guidelines, Lifetime Risk, Tyrer Cuzick
Yes. The intent of the guidelines was to look for younger women with a high long term risk, which is why they used lifetime risk. This means that older women with a high short term risk but a low lifetime risk are not eligible. MRI eligibility by age. Percent of...
by kshughes | Mar 3, 2016 | Boadicea, BRCAPRO, Claus, Guidelines, Tyrer Cuzick
NCCN guidelines recognize Tyrer Cuzick, Claus, BRCAPRO and Boadicea. Gail is not recognized as appropriate. National Comprehensive Cancer Network. Available The American Cancer Society (ACS) recognizes Tyrer Cuzick, Claus, and BRCAPRO. American Cancer Society in its...
by kshughes | Mar 3, 2016 | Boadicea, BRCAPRO, Claus, Guidelines, Tyrer Cuzick
Despite Gail being inadequate and not approved by either the National Comprehensive Cancer Network (NCCN) or the American Cancer Society (ACS) guidelines, some insurance companies do accept it. The right models are BRCAPRO, Tyrer Cuzick and Claus. Boadicea has...
by kshughes | Mar 3, 2016 | Genetic Testing, Guidelines, Lifetime Risk, MRI, Population Level Risk, Tyrer Cuzick
Risk is defined in 2 ways: Risk of mutation (If risk of mutation is 10% or greater consider genetic testing) Risk of breast cancer (If lifetime risk of breast cancer is 20% or greater get an MRI) 4% of your population getting mammography will need genetic testing For...
by kshughes | Mar 3, 2016 | BRCAPRO, Claus, Gail, Genetic Testing, Guidelines, Lifetime Risk, MRI, Population Level Risk, Tyrer Cuzick
If you use Tyrer Cuzick7, about 15% will need an MRI. If you use Claus, about 0.9% will need an MRI. If you use BRCAPRO, about 0.5% will need an MRI. [ASCO_2014_NCCNB_BRCAPRO_TyrerCuzickRiskMutationsLifetimeRisk]
by kshughes | Mar 3, 2016 | Genetic Testing, Guidelines, Hughes RiskApps, Hughes RiskApps Express, MRI, Population Level Risk
Although the survey asks patients about their atypia, LCIS status and past genetic test results, the self-reported response is NOT accepted as true until verified by the user. Risk calculations are not run nor presented in the survey summary until the clinician or...
